Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
| Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
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
U8tub9NakY8TMvKu
Listen
